Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Although fist-line therapy with Cisplatin and etoposide(EP)or Carboplatin and
etoposide(CE)and second-line therapy with topotecan has been given, patients with ED-SCLC
still relapse and 2-year survival is less than 10%. There is no standard treatment
recommendation for this group of patients who failed to second-line therapy and had good
performance status. Some cytotoxic drugs for the treatment of non-small cell lung cancer,
i.e. vinorelbine, paclitaxel, and ifosfamide, were used in refractory or recurrent SCLC
patients. Recently, a retrospective study showed the overall response rate was 30%, the
median progression free survival (PFS) was 6.5 months, and the median overall survival was
10.4 months in advanced combined SCLC patients treated with first-line regimen of
vinorelbine, ifosfamide and cisplatin (NIP). Because of the previous platinum administration
and patient's performance status, only vinorelbine and ifosfamide (NI) are combined and used
as third-line therapy for refractor or recurrent ED-SCLC in our lung cancer center. And this
clinical trial is designed to prospectively investigate the efficacy and safety of NI regimen
in refractory or recurrent ED-SCLC patients in our center.